Critical Collaborators
This article was originally published in RPM Report
Executive Summary
The Food & Drug Administration's dream of identifying a "critical path" to improve drug development productivity is one step closer to moving from rhetoric to reality. Three months after the official blessing from the Department of Health & Human Services for an effort by the C-Path Institute (in Tucson, Arizona) to create a consortium to validate preclinical toxicity test methods, C-Path has signed on nearly a dozen willing participants from big pharma.